Survival outcomes were estimated with Kaplan-Meier curves. Results: Forty patients were included in final analysis. At baseline the median tumor marker carbohydrate antigen CA levels were About In The median progression free survival PFS and median overall survival were 8.
Conclusions: Baseline CA levels are significantly correlated with overall survival of patients affected by LPAC and BRPC, suggesting that this evaluation could improve their clinical management and the decision making. Further investigations and multivariate analysis are needed to confirm these data. Bursi S. Background: Treatment outcomes and survival for patients with biliary tract cancers BTCs have improved little over the past three decades.
Approximately half of untreated patients die within 3—4 months of presentation from the indirect effects of local tumor progression, bile duct obstruction, liver failure or sepsis from cholangitis and abscesses. Hepatic arterial infusion of chemotherapy HAI gets better pharmacokinetics outcome with some compounds that have a very high vascular extraction ratio on first pass removal. Patients and methods: This is an observational, single-center, retrospective analysis of HAI associated to systemic fluoropyrimidines-based chemotherapy sCT for patients with locally advanced or metastatic BTCs.
HAI provided the loco-regional infusion of epirubicin and cisplatin. The median age was In 37 There were no difference in median progression-free survival mPFS and overall survival OS according to primary tumor site.
Overall, pre and post treatment median performance status and median CA Conclusions: In our series most of patients were treated with HAI as first-line treatment before the evidence of efficacy of cisplatin and gemcitabine doublet. However, this analysis has demonstrated an interesting activity of HAI associated with sCT despite the line of treatment, and confirms the fundamental role of surgery for a good outcome in BTCs.
Cavanna L. Metastatic pancreatic adenocarcinoma has a very poor prognosis. Santaniello A.
- 2 Peter?
- Islam and the Glorious Ka’abah.
- Bug made in France: ou Lhistoire dune capitulation culturelle (Hors série Connaissance) (French Edition)?
- The Bible, the School, and the Constitution: The Clash that Shaped Modern Church-State Doctrine.
- Mystery at the Bed and Breakfast!
Background: Metastatic pancreatic cancer PC has a dismal prognosis, with a median overall survival mOS of about 6 months without systemic therapy. The aim of our study is to evaluate the efficacy and the toxicity profile in patients treated with these therapies in a real word setting.
Median PFS was Median OS was Only one patient treated with GnP reached a complete response.
Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM)
Incidence of major adverse events G3 or more appears similar in both the FFN and GnP groups, excluding anaemia, lower extremities oedema and thrombocytosis which are more frequent or even exclusive in the GnP group. Rimassa L. Cabozantinib may promote an immune-permissive tumor environment, which could enhance response to immune checkpoint inhibitors. Cabozantinib in combination with the anti-PD-L1 antibody atezolizumab is being evaluated in multiple tumor types including HCC in a phase 1 study; recommended dose, preliminary clinical activity, and safety of the combination have been demonstrated in aRCC Agarwal Ann Oncol Additional endpoints include safety, pharmacokinetics, and correlation of biomarker analyses with clinical outcomes.
The first patient was enrolled in December , and enrollment is ongoing. Belloni P. Background: Esophageal cancer is a very aggressive tumor, most patients are often not fit enough to receive second line chemotherapy, and even in this case results are dismall with poor response and short survival. A retrospective analysis of all consecutive patients with AEC followed at the our Medical Oncology Unit between from February and January was performed.
Methods: a total number of 14 AEC patients treated with one chemotherapy line were eligible for the analysis. Histological type was Squamous cell carcinoma 8SCC in all patients. We observed 5 stable disease, 4 progressive disease and 5 objective response. Median time to progression was 5.
All patients was evaluable for survival median overall survival 8. No life threatening event occurred. Teatment was well tolerated from the great part of patients and the main toxicities were low-grade G1-G2. Few patients reported severe G3-G4 adverse events such as fatigue 2 pts , thrombocytopenia 1 pts , peripheral neuropathy 2 pts. Conclusions: the study suggest that GEMVIN schedule in effective and well tolerated, and may prolog survival with a relatively good quality of life in patients with AEC previously exposed to one chemotherapy line.
Giuffrida D. Introduction: GEC is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. Until not long ago, surgery was considered the only curative treatment for GEC.
However, the results are still unsatisfactory, due to the high rate of metastasis and relapse. Chemotherapy together with surgery has shown promising results. Randomized studies proved that perioperative chemotherapy provides a survival benefit over surgery alone and should be considered the standard of care in potentially operable GEC.
TRG tumour regression grade sec. Conclusions: Our real-life experience shows that the perioperative FLOT appears to be effective and safe. It would be useful to evaluate prospectively the microsatellite instability as predictive factor to treatment response. Faloppi L. Background: For over ten years the most stimulating results in systemic therapy for advanced HCC derived from the use of sorafenib S. But in the last two years several drugs, in particular other multikinase inhibitors like lenvatinib L , regorafenib R , cabozantinib C , proved to be effective both as an alternative or a sequential therapy to sorafenib.
In this widened and rapidly increased scenario, without any head-to-head trial, clinicians struggle to define the best drug and the best treatment sequence. Aim of the first part of this project is to evaluate the activity of different treatment sequences in HCC cell lines to pave the way to a future clinical trial investigating their efficacy. After 24 h of incubation, compounds or vehicle DMSO were added. Treatments were performed in single administration and six replicates were carried out for each dose.
At 48h post-treatment, cells were fixed and stained with acid solution. Higher doses than the minimum inhibiting one were tested. Results: S showed superior activity than L as first line compound. In the sequence assay S-C and S-R seems to have the best results in terms of cell viability.
After L the best compound appears to be R. See table. Conclusions: Our results showed relevant variations in cell viability with different drug sequences. Already planned analyses in the RISE-HEP project in vivo and in humans are mandatory to confirm which sequence would have the highest efficacy. Camera S.
- Granada (German Edition).
- Der göttliche Held mit dem Rücken zur Kirche - Don Fernandos Rolle in einer unerträglichen Welt (German Edition).
- The Knowledge: A free digital compendium.
- Haleys Anatomy, Part 1 (Professor, Student, Medical, College, School, Romance, New Adult) (Naughty Medicine).
- Janus et autres histoires de coeurs extraordinaires (French Edition)?
- Plaisir dAmour!
- Notes on Certain Maya and Mexican Manuscripts Third Annual Report of the Bureau of Ethnology to the Secretary of the Smithsonian Institution, 1881-82, ... Office, Washington, 1884, pages 3-66.
Background: Gastric cancer is one of the most frequent neoplasias with an aggressive behavior. Long-term outcome after surgery alone is poor, therefore a combined treatment approach is the standard of care. Here, we report the results of efficacy and safety of FLOT regimen in our real-life experience. We also evaluated neutrophil-lymphocite ratio NLR , marker of inflammation associated with worse OS in solid tumours. Median age 64 years range The median duration of treatment was 4 cycles. We observed a significantly higher mOS in pts with cT No case of neutropenia was registered.
All pts received peg-G-CSF.
No patient interrupted chemotherapy due to toxicity. Were not differences in terms of AE between young and elderly pts. Surgery was performed in Preoperative FLOT is ongoing for 2 pts.
Conclusions: Despite the limited sample size, our real-life experience confirm that perioperative FLOT is an effective and well tolerated regimen with a significant benefit in survival outcome and a good safety profile, in line with the results of FLOT trial. Introduction: Pancreatic cancer PC is the fifth most lethal cancer. Identifying prognostic factors is important to layer individual risk. The overall survival OS varies from 4,2 to 13,2 moths. Neutropenia and diarrhea are the most frequent toxicities.
Several evidences suggest that a high NLR is related to an adverse outcome.
They received a median of 6,5 range drug administrations. Detected toxicity G was neutropenia and diarrhea in 3 and 1 patients, respectively. Conclusions: Our experience shows that Nab Paclitaxel-Gemcitabine in the first line is an active and well tolerated regimen, allowing about a third of the patients to receive a second-line treatment. We are expecting new prognostic factors could be a guidance to choice the treatment. Conte B. Luminal A and luminal B subtypes have different sensitivity to neo adjuvant chemotherapy; however, their role in predicting DD efficacy in clinically high-risk setting is uncertain.
After a median follow-up of 8 years, DFS was Conclusions: These long-term results confirm the prognostic value of IHC-defined luminal subtypes, with luminal B-like bearing a worse prognosis.